

Chinese firms to advance drug development for hard-to-drug molecular targets

09 August 2021 | News

A synergistic alliance between a biopharmaceutical company and an innovative AI-powered drug discovery company to transform drug discovery and development.



Hong Kong's Antengene Corporation Limited, a biopharmaceutical company focused on hematology and oncology drugs is entering a long-term partnership with MindRank AI, an innovative AI drug discovery company to develop first-in-class small-molecule oncology drugs.

Antengene has a strong R&D team with global experience in the discovery and development of innovative drugs and proven capability in developing compounds for difficult-to-drug targets. To date, Antengene has built a broad and expanding pipeline of 13 clinical and pre-clinical assets, comprising 8 global rights assets and 5 assets with rights for Asia Pacific markets including the Greater China region.

Meanwhile, MindRank AI will deploy its proprietary one-stop AI-driven drug discovery platform, Molecule Pro™, and its molecular dynamics platform, Molecule Dance™, to support Antengene's efforts in discovering and developing more first-in-class and best-in-class drug candidates.

Through this collaboration to advance the development of difficult-to-drug targets, Antengene and MindRank AI aim to improve the efficiency and success rate of the current drug discovery process. Both parties hope to address more unmet medical needs by delivering practice-changing therapeutics for patients.